Teva CEO Sees Bright Future, Eyes Larger Acquisitions
Translated & summarized from Globes by baba
Teva's President and CEO Richard Francis announced a promising future for the company, projecting innovative drug revenues to reach $6-7 billion by 2030. He highlighted Teva's transformation into a biopharma company and positive feedback from investors at a recent R&D day. Francis also indicated that Teva is exploring larger acquisitions and will continue to invest in its generics and biosimilars business.
The story in 5 lines · by baba
- Teva CEO Richard Francis sees a "especially promising" future and is considering larger acquisitions.
- Innovative drug revenue target raised to $6-7 billion by 2030, up from $5 billion.
- Teva has transformed from a generics company to a biopharma company, investors report.
- Positive feedback received from investors and analysts at the company's R&D day.
- Teva will continue to invest in and grow its generics and biosimilars business.
Teva's President and CEO, Richard Francis, expressed strong optimism about the company's future, stating that "the future looks especially promising" following the company's R&D day in New York. He believes it's a good time to evaluate Teva as an analyst, investor, or employee.
Francis highlighted Teva's progress since launching its "Pivot to Growth" strategy, which focuses on innovative products. The company has updated its revenue target for innovative drugs to $6-7 billion by 2030, up from a previous estimate of around $5 billion. In 2022, innovative drugs accounted for 9% of revenue, projected to reach about 20% this year, and are expected to exceed 25% of total revenue by 2030. The number of innovative assets in Teva's market portfolio has grown from two in 2022 to four currently, with a potential of nine by 2030. Free cash flow is projected to exceed $3.5 billion by 2030, compared to approximately $2 billion this year.
Francis explained that Teva has transformed from a generics-focused company to a biopharma company, showcasing its strong pipeline and commercial capabilities. Feedback from investors and analysts at the R&D day was reportedly very positive, with some expressing pleasant surprise at the quality of the products. Francis acknowledged that investors have been cautious due to Teva's past challenges but expressed confidence that the company will prove its potential, eventually making the Teva brand synonymous with quality medicine and execution.
Regarding future development, Francis indicated potential for more agreements similar to the financing deal with Royalty Pharma to accelerate drug development. He also confirmed that Teva is continuously evaluating external opportunities, including larger business development deals, emphasizing a disciplined approach to acquisitions. Francis also reaffirmed the importance of Teva's generics and biosimilars business, stating it remains a core pillar of the company's strategy and will see continued investment and growth.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
